In the first article of a 2-part series, Hayder Saeed, MD, discusses the 5-year follow up data from the L-MIND study, which shows the continuing efficacy of tafasitamab and lenalidomide for patients with relapsed/refractory diffuse large B-cell lymphoma.
CASE
Targeted Oncology: What led to the approval of tafasitamab (Monjuvi) and lenalidomide (Revlimid) for patients with relapsed/refractory DLBCL?
HAYDER SAEED, MD: Tafasitamab plus lenalidomide was approved based on the L-MIND study [NCT02399085].1 This study enrolled patients with relapsed/refractory DLBCL who had 1 to 3 prior lines of treatment and were not eligible for stem cell transplant. Primary refractory patients were excluded initially, and those [were defined as patients] who were refractory to frontline therapy within 3 to 6 months. Patients [on the trial] first received first 12 mg/kg of tafasitamab weekly for the first 3 cycles and then it was done every other week subsequently, until disease progression. They all received lenalidomide for 1 year and lenalidomide was encouraged to stay around 25 mg per day.
We all have difficulty with maintaining lenalidomide at 25 mg per day, [because of the] toxicity associated with it. It’s OK if some patients will have to drop to 20 mg or if you have to drop to 15 mg, but this is one of those situations where you try to maintain your dose at least at 20 mg to 15 mg, because data have shown that the lower dose of lenalidomide has less efficacy for patients with DLBCL.1
Were there any efficacy changes at the 5-year follow-up of these data?
Between the initial release [of the data] in 2018 and the subsequent [5 year follow-up] release, there was really no difference in outcome.2 The overall response rate [ORR] at 5 years was 57.5% [95% CI, 45.9%-68.5%], the complete response [CR] rate was at 41.3% [95% CI, 30.4%-52.8%], and the rate of partial responses is at 16.3% [95% CI, 8.9%-26.2%]. The duration of response was not reached in the updated 5-year data. For the patients who responded, their median progression-free survival [PFS] was 11.6 months [95% CI, 5.7-45.7] and stayed stable.
If you look at the difference...between the patients who received this regimen in the second line vs third line and fourth line, there was a significant difference in their outcomes. [For example], those patients who received [tafasitamab plus lenalidomide] in the second line will have a median PFS of 23.5 months [95% CI, 7.4–not reached (NR)] compared with 7.6 months [95% CI, 2.7-45.5] in those who received the treatment in the third- or fourth-line [of therapy].2
How do you know which patients who are refractory to frontline therapy will have a good outcome with this combination treatment?
This is what the [trial was powered for], to…find the right patients that would respond to this combination regimen. The good thing is that...within the first 3 months of treatment you will probably know which one your patient...will respond to this treatment and have a pretty good chance of having a long remission vs those who will drop off and will move on to other lines of treatment.
So that's why it's not a regimen that will perfectly fit every patient you have with relapsed/refractory DLBCL, but I think it will have a role in a pretty good number of patients. The right patient [could include those] with less bulky disease in whom you discover the disease earlier; maybe they are not candidates for CAR T-cell therapy for one reason or the other, or they're an elderly patient who...doesn't want to disrupt their life. Patients who are not primary refractory but might benefit from this treatment if they do respond the next 3 to 6 months [after treatment initiation].
References:
1. Salles G, Duell J, González Barca E, et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol. 2020;21(7):978-988. doi:10.1016/S1470-2045(20)30225-4
2. Duell J, Abrisqueta P, Andre M, et al. Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: final 5-year efficacy and safety in the phase II L-MIND study. Haematologica. 2023. doi:10.3324/haematol.2023.283480
Triplets and Quadruplets Now Play Role in Transplant-Ineligible NDMM
October 2nd 2024During a Case-Based Roundtable® event, Andrzej Jakubowiak, MD, PhD, surveyed how newer regimens influence a patient case of a 79-year-old with newly diagnosed multiple myeloma in the second article of a 2-part series.
Read More
Five-Year Data Shows CheckMate 9LA Regimen Maintains Survival in NSCLC
September 24th 2024During a Case-Based Roundtable® event, Ticiana Leal, MD, discusses combination therapy with nivolumab plus ipilimumab and chemotherapy for patients with non–small cell lung cancer in the first article of a 2-part series.
Read More
Lunning Evaluates CAR T-Cell Therapy for ASCT-Eligible and Ineligible DLBCL
September 22nd 2024During a Case-Based Roundtable® event, Matthew A. Lunning, DO, discussed the updated trial data for 2 chimeric antigen receptor T-cell therapies in patients with diffuse large B-cell lymphoma.
Read More
Efficacy of Cilta-Cel Is Maintained in Early Relapsed Multiple Myeloma
September 20th 2024During a Case-Based Roundtable® event, Samer A. Al'Hadidi, MD, MS, discussed the CARTITUDE-4 trial of cilta-cel in patients with relapsed/refractory multiple myeloma in the first article of a 2-part series.
Read More